Loss of AT-rich interactive domain 1A expression in gastrointestinal malignancies

Oncology (Switzerland)

Volumn 88, Issue 4, 2014, Pages 234-240

  Lee, Soo Young ^a   Kim, Duck Woo ^b,c   Lee, Hye Seung ^b   Ihn, Myong Hoon ^b   Oh, Heung Kwon ^b   Park, Do Joong ^b   Kim, Hyung Ho ^b   Kang, Sung Bum ^b  

^a Chonnam National University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

AT rich interactive domain 1A; Colorectal cancer; Gastric cancer; Prognosis

Indexed keywords

AT RICH INTERACTIVE DOMAIN 1A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ARID1A PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ARTICLE; AT RICH SEQUENCE; CANCER PROGNOSIS; COLORECTAL CANCER; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; LYMPH VESSEL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR INVASION; TUMOR VOLUME; CANCER STAGING; ENZYME IMMUNOASSAY; FOLLOW UP; GASTROINTESTINAL NEOPLASMS; METABOLISM; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE;

COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84926416619     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000369140     Document Type: Article

References (35)

1. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih Ie M, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG: ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-1543.
2. Reisman D, Glaros S, Thompson EA: The SWI/SNF complex and cancer. Oncogene 2009; 28: 1653-1668.
3. Nagl NG Jr, Patsialou A, Haines DS, Dallas PB, Beck GR Jr, Moran E: The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. Cancer Res 2005; 65: 9236-9244.
4. Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330: 228-231.
5. Maeda D, Mao TL, Fukayama M, Nakagawa S, Yano T, Taketani Y, Shih Ie M: Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci 2010; 11: 5120-5128.
6. Fadare O, Renshaw IL, Liang SX: Does the loss of ARID1A (BAF-250a) expression in endometrial clear cell carcinomas have any clinicopathologic significance? A pilot assessment. J Cancer 2012; 3: 129-136.
7. Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D, Hruban RH, Eshleman JR, Iacobuzio-Donahue CA, Goggins M, Maitra A, Malek SN, Powell S, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N: Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat 2012; 33: 100-103.
8. Zhang X, Zhang Y, Yang Y, Niu M, Sun S, Ji H, Ma Y, Yao G, Jiang Y, Shan M, Zhang G, Pang D: Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance. Cancer Epidemiol 2012; 36: 288-293.
9. Zhao J, Liu C, Zhao Z: ARID1A: a potential prognostic factor for breast cancer. Tumour Biol 2014; 35: 4813-4819.
10. Katagiri A, Nakayama K, Rahman MT, Rahman M, Katagiri H, Nakayama N, Ishikawa M, Ishibashi T, Iida K, Kobayashi H, Otsuki Y, Nakayama S, Miyazaki K: Loss of ARID1A expression is related to shorter progressionfree survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol 2012; 25: 282-288.
11. Zhang ZM, Xiao S, Sun GY, Liu YP, Zhang FH, Yang HF, Li J, Qiu HB, Liu Y, Zhang C, Kang S, Shan BE: The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma. Int J Gynecol Cancer 2014; 24: 534-540.
12. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY, Lee SP, Ho SL, Chan AK, Cheng GH, Roberts PC, Rejto PA, Gibson NW, Pocalyko DJ, Mao M, Xu J, Leung SY: Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011; 43: 1219-1223.
13. Abe H, Maeda D, Hino R, Otake Y, Isogai M, Ushiku AS, Matsusaka K, Kunita A, Ushiku T, Uozaki H, Tateishi Y, Hishima T, Iwasaki Y, Ishikawa S, Fukayama M: ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability. Virchows Arch 2012; 461: 367-377.
14. Wang DD, Chen YB, Pan K, Wang W, Chen SP, Chen JG, Zhao JJ, Lv L, Pan QZ, Li YQ, Wang QJ, Huang LX, Ke ML, He J, Xia JC: Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One 2012; 7:e40364.
15. Kim MS, Je EM, Yoo NJ, Lee SH: Loss of ARID1A expression is uncommon in gastric, colorectal, and prostate cancers. APMIS 2012; 120: 1020-1022.
16. Wiegand KC, Sy K, Kalloger SE, Li-Chang H, Woods R, Kumar A, Streutker CJ, Hafezi-Bakhtiari S, Zhou C, Lim HJ, Huntsman DG, Clarke B, Schaeffer DF: ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. Hum Pathol 2014; 45: 1258-1268.
17. Chou A, Toon CW, Clarkson A, Sioson L, Houang M, Watson N, DeSilva K, Gill AJ: Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. Hum Pathol 2014; 45: 1697-1703.
18. Choi YS, Lee SI, Lee TG, Kim SW, Cheon G, Kang SB: Economic outcomes of laparoscopic versus open surgery for colorectal cancer in Korea. Surg Today 2007; 37: 127-132.
19. Jeong SY, Park JW, Nam BH, Kim S, Kang SB, Lim SB, Choi HS, Kim DW, Chang HJ, Kim DY, Jung KH, Kim TY, Kang GH, Chie EK, Kim SY, Sohn DK, Kim DH, Kim JS, Lee HS, Kim JH, Oh JH: Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol 2014; 15: 767-774.
20. Lee JH, Lee CM, Son SY, Ahn SH, Park-do J, Kim HH: Laparoscopic versus open gastrectomy for gastric cancer: long-term oncologic results. Surgery 2014; 155: 154-164.
21. Oh JR, Kim DW, Lee HS, Lee HE, Lee SM, Jang JH, Kang SB, Ku JL, Jeong SY, Park JG: Microsatellite instability testing in Korean patients with colorectal cancer. Fam Cancer 2012; 11: 459-466.
22. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-268.
23. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, Lim KH, Ong CK, Huang D, Chin SY, Tan IB, Ng CC, Yu W, Wu Y, Lee M, Wu J, Poh D, Wan WK, Rha SY, So J, Salto-Tellez M, Yeoh KG, Wong WK, Zhu YJ, Futreal PA, Pang B, Ruan Y, Hillmer AM, Bertrand D, Nagarajan N, Rozen S, Teh BT, Tan P: Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012; 44: 570-574.
24. Nagl NG Jr, Wang X, Patsialou A, Van Scoy M, Moran E: Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. EMBO J 2007; 26: 752-763.
25. Gao X, Tate P, Hu P, Tjian R, Skarnes WC, Wang Z: ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a. Proc Natl Acad Sci USA 2008; 105: 6656-6661.
26. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang X, Hinkle G, Boehm JS, Beroukhim R, Weir BA, Mermel C, Barbie DA, Awad T, Zhou X, Nguyen T, Piqani B, Li C, Golub TR, Meyerson M, Hacohen N, Hahn WC, Lander ES, Sabatini DM, Root DE: Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA 2008; 105: 20380-20385.
27. Guan B, Wang TL, Shih Ie M: ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 2011; 71: 6718-6727.
28. Rahman M, Nakayama K, Rahman MT, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Miyazaki K: Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer. Hum Pathol 2013; 44: 103-109.
29. Bosse T, ter Haar NT, Seeber LM, Diest PJ, Hes FJ, Vasen HF, Nout RA, Creutzberg CL, Morreau H, Smit VT: Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol 2013; 26: 1525-1535.
30. Lee HS, Choe G, Park KU, Park do J, Yang HK, Lee BL, Kim WH: Altered expression of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) during gastric carcinogenesis and its clinical implications on gastric cancer. Int J Oncol 2007; 31: 859-866.
31. Mao TL, Shih Ie M: The roles of ARID1A in gynecologic cancer. J Gynecol Oncol 2013; 24: 376-381.
32. Huh JW, Lee JH, Kim HR, Kim YJ: Prognostic significance of lymphovascular or perineural invasion in patients with locally advanced colorectal cancer. Am J Surg 2013; 206: 758-763.
33. Morikawa T, Kuchiba A, Qian ZR, Mino-Kenudson M, Hornick JL, Yamauchi M, Imamura Y, Liao X, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S: Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol 2012; 19: 1944-1953.
34. Luebke T, Baldus SE, Grass G, Bollschweiler E, Thiele J, Dienes HP, Hoelscher AH, Moenig SP: Histological grading in gastric cancer by Ming classification: correlation with histopathological subtypes, metastasis, and prognosis. World J Surg 2005; 29: 1422-1427, discussion 1428.
35. Guan B, Suryo Rahmanto Y, Wu RC, Wang Y, Wang Z, Wang TL, Shih Ie M: Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J Natl Cancer Inst 2014; 106.